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Abstract
Background/Aims: To explore different definitions of intra-individual variability (IIV) to summarize performance on
commonly utilized cognitive tests (Mini Mental State Exam; Clock Drawing Test); compare them and their potential to
differentiate clinically-defined populations; and to examine their utility in predicting clinical change in individuals from the
Alzheimer’s Disease Neuroimaging Initiative (ADNI).
Methods: Sample statistics were computed from ADNI cohorts with no cognitive diagnosis, a diagnosis of mild cognitive
impairment (MCI), and a diagnosis of possible or probable Alzheimer’s disease (AD). Nine different definitions of IIV were
computed for each sample, and standardized effect sizes (Cohen’s d) were computed for each of these definitions in 500
simulated replicates using scores on the Mini Mental State Exam and Clock Drawing Test. IIV was computed based on test
items separately (‘within test’ IIV) and the two tests together (‘across test’ IIV). The best performing definition was then used
to compute IIV for a third test, the Alzheimer’s Disease Assessment Scale-Cognitive, and the simulations and effect sizes
were again computed. All effect size estimates based on simulated data were compared to those computed based on the
total scores in the observed data. Association between total score and IIV summaries of the tests and the Clinician’s
Dementia Rating were estimated to test the utility of IIV in predicting clinically meaningful changes in the cohorts over 12-
and 24-month intervals.
Results: ES estimates differed substantially depending on the definition of IIV and the test(s) on which IIV was based. IIV
(coefficient of variation) summaries of MMSE and Clock-Drawing performed similarly to their total scores, the ADAS total
performed better than its IIV summary.
Conclusion: IIV can be computed within (items) or across (totals) items on commonly-utilized cognitive tests, and may
provide a useful additional summary measure of neuropsychological test performance.
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Introduction
Intra individual variability (IIV) is an important, although
underappreciated, aspect of cognitive testing and assessment in
elderly individuals who are either at risk for dementia or who have
a diagnosis and whose progress is being monitored via cognitive
tests [1,2]. IIV may be overlooked in neuropsychological research
and practice because estimates of IIV are almost always based on
reaction time and accuracy-based measures (e.g., [3]). Further,
there are multiple methods of defining IIV [2,4–6]; without a
single best way to compute IIV, it is challenging to introduce –or
use - as a summary outside of its most commonly-used context.
While total scores provide an estimate of overall performance
on cognitive measures, IIV measures can complement these scores
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e16973and may improve prediction of global decline [7], functional
decline [8], and incident dementia [9]. It has been suggested that
estimates of IIV provide a quantitative measure of neurobiological
integrity in cognitive aging and neurodegenerative disease [4,10–
13], as greater mean IIV levels have been reported in samples with
mild cognitive impairment [2] and mild dementia [1], and has
been found to associate with decreased frontal gray matter [14],
white matter alterations [15], and altered dopaminergic and
acetylcholinergic neurotransmission [11–12,16–17].
Researchers have been estimating, and interpreting, different
patient profiles in IIV with respect to reaction times and
‘‘accuracy’’ (i.e., right/wrong response summary) for at least a
decade (see [1,11–12,18–19]). By contrast, cross-domain versions
of IIV have also recently been used to estimate IIV using
neuropsychological tests (e.g., [7–9]). These IIV estimates have all
been based on a single formulation of IIV: within-subject standard
deviations across cognitive domains –subscales of one test or tests
within a battery. Results of these studies have shown that
performance on specific subscales of global cognitive tests, instead
of the overall score on the test, predicts cognitive change in
preclinical Alzheimer’s disease [20], and that cross-domain IIV
(within-subject standard deviation across subscale) summarizing
the test at baseline, predicts cognitive decline over an 18-month
period above and beyond mean score performance [7]. However,
separable factors or domains on tests such as the Mini-Mental
State exam (MMSE [21]) have not been reliably observed [22–24],
suggesting that IIV estimates based on subscores of the MMSE
might not be replicable.
Using the within-individual standard deviation (ISD) definition
of IIV, Rapp et al. [8] reported that cross-domain IIV, computed
from a battery of neuropsychological tests (i.e., task dispersion
[4,17]) predicted functional decline in both nursing home residents
and community-dwelling older adults. Similarly, Holtzer et al. [9]
found that across-test IIV predicted incident dementia indepen-
dent of mean level performance in a population-based study.
Hilborn et al. [6] also studied dispersion of performance across
tasks and found that this definition of IIV was significantly
associated with the likelihood of decline from estimated prior IQ,
particularly older old (75–92 years old), as well as with poorer
health and demographic characteristics. Using another definition
of IIV, Duchek et al. [25] found that within-test IIV (coefficient of
variation, not within-subject standard deviation), derived from
attention tasks, was associated with a genetic marker (ApoE) and
with cerebrospinal fluid biomarkers believed to be associated with
Alzheimer’s disease.
Focusing on items within a single cognitive test, Tractenberg,
Yumoto et al. [26] found that levels of IIV in item-level
performance on a commonly utilized measure of ‘‘global’’
cognitive function (Mini Mental State Exam (MMSE), [21]) over
a four year period was not reflected in test scores. This finding
suggests that this IIV estimate may explain unique variances in
impairment or decline, as the level of IIV was different for
different items on the same test depending on the diagnostic
category of the participants being analyzed (normal for four years;
normal at first, then diagnosed with AD; or diagnosed with AD
from the first visit). This finding further suggests that performance
variability as assessed by IIV estimates across items, tests, and/or
domains on commonly utilized cognitive tests, might be useful
markers of cognitive decline. That is, variability in performance
across items of a single neuropsychological test may provide a
reliable estimate of compromised neural integrity, similar to IIV
estimates derived from performance-related measures (e.g.,
attentional tasks; [25]). This within-test, across-item approach to
summarizing intraindividual test performance might have clinical
utility, since it may be used to compute estimates of IIV for
virtually any cognitive test irrespective of whether or not it
comprises reliable subtests; further, estimating IIV would not be
limited by the population within which factor analyses to identify
those subtests are conducted (e.g., for MMSE-subscore based
estimates).
If item-level IIV is useful as a proxy for neural integrity, then it
should also predict cognitive decline and impairment similar to the
prediction by the total score (sum of the item scores, usually 0 or
1); to our knowledge, no study has reported item-level IIV.
However, there are multiple methods for computing IIV. The
purpose of the present study was to explore a variety of definitions
and compare their effect sizes in order to determine which, if any,
could be a clinically useful summary of performance. Using data
from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), we
estimated effect sizes for three commonly-used definitions of
intraindividual variability (IIV), namely, intraindividual standard
deviation (i.e., computed standard deviation for items or for
standardized test scores per person), coefficient of variation (i.e.,
standard deviation divided by mean, either over all items or over
standardized test scores), and level-independent variation (i.e.,
variability independent of the individual’s predicted mean score).
We then compared these effect sizes to that derived for the
standard, total score-based approach to summarizing performance
on the MMSE and Clock Drawing Test-copy. These tests were
selected because they are commonly used in both research and
practice, and because they contain items that assess global
cognitive function based on assessment of various cognitive
domains, including language, memory, visuospatial, and executive
functions (MMSE: [24]; Clock Drawing: [27]). We further
analyzed a single test with specific subscores, the Alzheimer’s
Disease Assessment Scale – Cognitive (ADAS-Cog, [28]), to
compare results across these three different tests.
The primary purpose of this study was to estimate effect sizes
(ES) for different IIV definitions and to compare these values to
identify the most robust definition of (formula for) IIV derived
from cognitive tests, as well as to the ES for either tests’ total score.
The secondary purpose was to determine whether any of the
definitions of IIV were able to differentiate groups with three
different levels of disease burden that serve as proxies for structural
brain integrity – normal elderly, individuals with mild cognitive
impairment (MCI) and individuals with Alzheimer’s disease (AD).
We hypothesized that IIV would be an informative alternative
performance summary (as compared to the total test scores),
irrespective of whether it was derived from the items within a
single test or derived from multiple tests; because the MMSE is a
more ‘general’ test, with items that target a wider variety of
cognitive functions than the Clock Drawing Test, we expected that
IIV based on MMSE items would yield greater ES estimates than
IIV based on Clock Drawing Test items. We also estimated the
power of IIV, derived from MMSE, Clock Drawing, and ADAS,
to explain variability in change in overall cognitive functioning
using a global clinical measure, the Clinical Dementia Rating
(CDR, [29]) sum of boxes.
Methods
Ethics Statement
Data collection and sharing for this project was made possible
by the Alzheimer’s Disease Neuroimaging Initiative (ADNI). The
ADNI study is IRB approved at all participating institutions (see
http://www.adni-info.org/Scientists/ApplyForAccessToSamples.
aspx for application process to obtain access to this dataset).
Inclusion, exclusion criteria, the list of all sites at which IRB
Effect Sizes of Different Definitions of IIV
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descriptions are presented at http://www.alzheimers.org/clinical-
trials/fullrec.asp?PrimaryKey=208). The data were obtained de-
identified, and were analyzed anonymously.
Our study of the different definitions and formulations of IIV
proceeded with simulations based on the MMSE and Clock
Drawing Test, as total scores and as the composite of their
individual items representing the context of variability, with two
levels (within- and across-test). Within each context (within MMSE
items, within Clock items, and across the 2 tests’ total scores) we
computed three different definitions of IIV (described below). The
ADAS is often used as an outcome in clinical trials for treatments
in Alzheimer’s disease; another clinical outcome for clinical studies
and trials is the Clinical Dementia Rating (CDR [29]). Our study
of the performance of IIV with respect to the CDR included all
three tests.
Study parameters
Recent investigators [8–9] studying across-test IIV formulations
on common clinical tests have used the same definition of IIV: the
‘‘individual’s standard deviation’’ (ISD), or, the square root of the
variance within one person’s collected, standardized responses
(standardized total scores) on several tests of ‘‘cognitive function’’.
In this study, each individual’s standard deviation was derived
from the two total test scores (standardized) as well as a function of
the items on each of these tests singly. A second definition of IIV is
the coefficient of variation (CV=standard deviation/mean),
derived from both a pair of tests and from the items on the two
tests singly. A final definition of IIV was based on an indicator
developed by Christensen et al. 2005 [2], termed ‘‘mean-
independent variation’’, MIV, which estimates individual vari-
ability but factors out the individual’s mean performance. Because
it was impossible to recreate MIV specifically with the responses
that our data contained (MIV was based on hundreds of trials
within multiple blocks), MIV was approximated with a ‘‘level’’
independent measure of variability: each individual’s CV was
regressed on the total score of the test(s) from which the CV was
computed (either the test totals alone or the two standardized test
scores together), and the standardized residuals from these
regressions represent IIV with the effects of the total score, or
level of performance, partialled out. The positive valued
standardized residuals (each value was squared, then the square
root taken, to eliminate negative values) were used to represent this
level-independent estimate of IIV (LIV). When the two total test
scores were included in each of these three formulations of IIV,
their standardized versions were used and the standardization was
based on the mean and variance of the group to which the
participants belonged – that is, group scores were standardized
depending on the diagnostic cohort individuals came from. The
standardized residuals were used to represent this level-indepen-
dent estimate of IIV (LIV) because the two tests have different
scales and distributions. When the two total test scores were
included in each of these three formulations of IIV, their
standardized versions were used and the standardization was
based on the mean and variance of the respective diagnostic
groups.
The two factors (definition of IIV, with three levels; context of
variability, with two levels (within- and across-test)) yield a 362
design for the simulation. Since there were two tests, two different
item-level IIV formulations were possible, resulting in a 363
design shown in Table 1. The different definitions are outlined in
Table 2.
Simulation study design
Clinical data from ADNI (as of October 2008) were used in this
study. The baseline (or screening) visit values for items (0=wrong;
1=right) and total scores were obtained for individuals partici-
pating in the study on two tests; these were chosen because: a) they
were recorded in the data files at the item level; and b) they
represent a ‘global’ and a more ‘specific’ measure, so that we
might observe different results for IIV derived from the items in
each. Three types of IIV variables (see Tables 1 and 2) were
computed. Table 3 below shows the means and standard
deviations for the nine IIV values, plus the two tests’ total scores,
obtained from the three samples (individuals with a cognitive
diagnosis of ‘‘normal’’ (N, i.e., no clinical symptoms AND normal
test performance), ‘‘mild cognitive impairment’’ (MCI, i.e., clinical
diagnosis based on national criteria) or ‘‘Alzheimer’s disease’’ (AD,
i.e., clinical diagnosis based on national criteria), based on the
baseline visit values for the ADNI cohorts.
The means and SDs shown in Table 3 are the sample values for
our observed data and represent the summaries (totals, or IIV
formulations) that were obtained from the original data. These
values were used as ‘‘population parameters’’ to seed the
simulations. Based on these values (means and SDs), 500
observations were sampled at random from within each of the
three ‘populations’ of summaries assumed to follow normal
distributions with the specified mean and SD. This created 500
of each type of test summary from the specified distribution. From
these 500 ‘‘observations’’ from the specified distribution, we
computed the mean and variance to estimate a single effect size
based on N=500 simulated observations. We then replicated that
effect size estimation 500 times, in effect creating a sampling
distribution of effect sizes representing the specific comparison
Table 1. Designs and definitions for the simulation.
Context of variability
Based on items within a single test
Based on the total scores
(standardized) on the 2 tests
Definition of
intra-individual variability
ISD (individual’s
standard deviation)
SD for ith subject across
all items on test 1
SD for ith subject across
items on test 2
SD for ith subject, based on tests 1 & 2
standardized total scores
CV (coefficient of variation) SD/mean for ith subject,
items on test 1
SD/mean for ith subject,
items on test 2
SD/mean for ith subject, based on tests
1 & 2 standardized total scores
LIV (‘level’-independent
variation)
Residual for ith subject,
CV,total, test 1
Residual for ith subject,
CV,total, test 2
Residual for ith subject, CV,totals,
based on tests 1 & 2 standardized total
scores
doi:10.1371/journal.pone.0016973.t001
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observations because it is a reasonably large value given the size of
longitudinal studies of aging around the country and the world;
our results must be reasonable (replicable) by other investigators in
this domain and large samples might artificially inflate the
precision of estimates.
Based on the three diagnostic groups and the 500 samples
simulated for each of the summaries shown in Table 3, two
effect sizes were computed in 500 replicated sampling simula-
tions to create the effect size sampling distributions for each
of the nine IIV formulations: one comparing the N and MCI
groups, and one comparing the MCI and AD groups. The
outcome of interest in the simulations was an effect size
(Cohen’s d [30]) derived from each simulated replication
(d~
 x x1{ x x2
s
,s~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(n1{1)s2
1z(n2{1)s2
2
n1zn2{2
s
) [31], with simulated-
sample means and variances and the common group size of
n=500). The effect sizes for AD vs N groups were not evaluated
because these two populations are usually easily distinguished. The
difficulty, and where the concept of IIV could be most important
in future research, is in differentiating the most difficult-to-
distinguish groups, which are the ones in adjacent categories, so
ES estimates for adjacent diagnostic categories were deemed most
interesting for the simulation.
Based on the results of the simulation, we then computed IIV
using the single best-supported IIV formula for the observed
responses on the MMSE and Clock Drawing Test; we added a
third test, the Alzheimer’s Disease Assessment Scale-Cognitive
(ADAS-Cog [28]) to this analysis, because it is the only one of the
three specifically designed for this disease population. We
computed multiple regressions (using SPSS v. 17.x, SPSS, Inc.
Chicago, Ill) to estimated the power of IIV to explain variability in
overall cognitive functioning at baseline, as well as in change in
cognitive functioning, using a global clinical measure, the Clinical
Dementia Rating (CDR [29]) sum of box scores.
Results
Table 4 shows the mean of the 500 effect sizes estimated (based
on the 500 simulated ‘‘observations’’) for each of the nine IIV
definitions and the two comparisons.
Table 5 presents the correlations, based on the observed sample
data, between the two total scores and the relevant IIV
formulations, by diagnostic group. Table 5, which does not
represent the simulated data, also shows that ISD versions of IIV
are more weakly associated with the respective total test scores
than are the CV versions of IIV, although the ISD and CV values
Table 3. Means and SDs ( x x(sd)) for IIV definitions; these
values are the actual sample values from the observed data
and were used as ‘‘population parameters’’ for simulations.
NORMAL MCI AD
Total score MMSE 29.11 (0.998) 27.01 (1.789) 23.28 (2.037)
Total score, Clock 9.50 (1.149) 8.81 (1.430) 7.71 (2.025)
ISD MMSE items 0.1246 (0.1143) 0.2784 (0.1078) 0.4159 (0.0465)
ISD Clock items 0.1037 (0.1806) 0.2257 (0.2077) 0.3405 (0.0465)
ISD, 2 total scores 13.8704 (0.9553) 12.8757 (1.4109) 11.0091 (1.7321)
CV MMSE items 0.1324 (0.1239) 0.3179 (0.1360) 0.5455 (0.1085)
CV Clock items 0.1275 (0.2353) 0.3082 (0.3267) 0.5637 (0.4756)
CV, 2 total scores 0.7205 (.0726) 0.7215 (0.0901) 0.7193 (0.1481)
LIV MMSE item cv 0.8714 (0.4827) 0.7346 (0.6757) 0.8383 (0.5369)
LIV Clock items cv 0.7239 (0.6850) 0.8979 (0.4350) 0.6314 (0.7706)
LIV, 2 total score cvs 0.5706 (0.8150) 0.6964 (0.7133) 0.7484 (0.6528)
NOTE: ISD and CV values involving total scores were based on standardized
totals on the two tests (using diagnostic group-specific means and SDs). LIV was
obtained as the square root of the squared standardized residuals from the
regression of the CV on the total score of the test (or, on both total scores, for
the 3
rd LIV value)- LIV values were all positive (H. Christensen, personal
communication).
doi:10.1371/journal.pone.0016973.t003
Table 2. Definitions and interpretations of IIV formulae.
Context of variability
Based on items within a single test
Based on the total scores
(standardized) on the 2 tests
Definition of
intra-individual
variability
ISD (individual’s standard deviation)
SD~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ P
(xi{ x x)
2
N
s The sum of squared differences
between each item’s response and
the average over all items on the test.
The sum of squared differences between
the ISDs for each test (xi) and the average
over both tests ( x x).
Like in any distribution, the standard deviation describes how an individual’s responses vary relative to their mean. SD is not ‘‘corrected’’ for overall
performance. If overall performance limits the amount of variability that can be exhibited (e.g., all right/all wrong will appear not to vary, and be
indistinguishable), the SD will not capture that.
CV (coefficient of variation)
CV~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ P
(xi{ x x)
2
N
q
 x x
The individual’s SD divided by the
individual’s average over all items
on the test ( x x).
The individual’s SD over two tests divided
by the individual’s average over the
two tests ( x x).
The coefficient of variation describes how an individual’s responses vary relative to their mean, but corrects for the individual’s overall
performance. This permits comparisons of the variability that remains after accounting for overall performance.
LIV (‘level’-independent variation)
e~
X
xi{ x x
The sum of 1/0 responses on items
(xi) minus the average over the
responses ( x x).
The standardized sums of 1/0 responses
on items, standardized for each test (xi),
minus the average over the responses
across all items on both tests ( x x).
Whereas CV accounts for overall performance by dividing by it, the LIV type formulation subtracts it. The independence of the variability from the
overall performance is estimated as the difference, rather than the quotient.
doi:10.1371/journal.pone.0016973.t002
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combined SD divided by their average) had weaker relationships
with the total scores than did the ISD and CV values based on the
items. Since higher scores on MMSE, but lower total Clock scores,
represent better function, the combination of positive and negative
correlations in Table 5 was expected. Table 5 also shows that LIV,
computed as positive values (i.e., the square roots of each squared
standardized residual values) retained significant relationships with
MMSE or Clock total scores; the LIV values for the averaged total
scores were not associated with MMSE total score, but LIV values
were significantly associated with Clock score in each group. Thus,
the LIV formulation of IIV was only partially ‘‘level independent.’’
T-tests were carried out to compare the effect sizes estimated for
each IIV definition with the ES derived from the total test score(s).
Every t-test was statistically significant; thus, in Figures 1A and 1B,
wherever one line falls above another, that mean effect size was
found to be significantly higher than the corresponding point
below it (all unadjusted p values,0.0001).
Visual inspection of Figures 1A and 1B reveals that, for both the
N vs MCI and MCI vs AD comparisons, the ES for total MMSE
was significantly larger than all IIV formulations, while the ES for
total Clock was significantly smaller than the mean ES for most of
the IIV formulations. It was observed that IIVs formulated as ISD
yielded a stronger ES than CV for Clock items only while CV
(mean corrected ISD) had a stronger ES than ISD when based on
MMSE items. The figures show that LIV – the formulation of IIV
with ‘level’ effects partialled out – produced the weakest ES in all
contexts.
Since the CV appears to have generated the most robust effect
sizes, we repeated the ES-simulation for baseline values of the
ADAS-Cog [20]. Baseline-derived ADAS IIV yielded a smaller ES
(N vs MCI: ES=0.742; MCI vs AD: ES=0.902) than the total
score (N vs MCI: ES=1.73; MCI vs AD: ES=1.67); thus the
effect sizes for the total score were significantly greater than for IIV
in this simulation, and also larger than might be expected
generally, just as with the MMSE. Table 6 presents the results of
linear regressions to estimate the relative explanatory power of
each total score the coefficient of variation (IIV) summary of the
same test (individually) at baseline for variability in change over 12
and 24 months in the CDR sum of box scores. In addition to the
individual (baseline, BL) summary explanatory power for change
in CDR, we estimated the BL IIV summary explanatory beyond
that of the total score.
Individually, IIV had lower R
2, relative to that of the total score,
to predict change in CDR sum of boxes 12 and 24 months after
the item responses were obtained, although IIV itself was a
statistically significant predictor of change in CDR sum of boxes
scores in all cases. The contributions of within-test IIV (coefficient
of variation) above and beyond the explanatory power of the total
test scores on the MMSE, Clock Drawing Test, and ADAS-Cog
for changes in cognitive symptomatology as reflected by changes in
CDR sum of boxes scores was statistically significant for the Clock
Drawing Test, which predicted change in CDR sum of boxes over
the 12-month interval, but the R
2 values were very small. Within-
test IIV estimates for the MMSE and ADAS-Cog were not
associated with change in CDR sum of boxes scores over the 12-
or 24-month intervals.
Discussion
The purpose of this study was to estimate effect sizes (ES) for a
set of IIV definitions and to determine which one provided the
most robust definition of IIV derived using commonly utilized
cognitive tests such as the MMSE and Clock Drawing Test.
Results of the study suggested that IIV is an informative alternative
performance summary (as compared to the total test scores),
irrespective of whether it is derived from the items within a single
test or from multiple tests. Consistent with our hypothesis, IIV
computations based on MMSE items yielded greater ES estimates
than IIV computations based on Clock Drawing Test items. The
IIV estimate derived from the Clock Drawing Test predicted
cognitive decline above and beyond mean scores on this test at a
12-month follow-up, but other IIV estimates did not.
To our knowledge, this is the first study to estimate effect sizes
for a variety of IIV formulations including within test (item-level)
estimation using commonly employed cognitive tests such as the
MMSE. Our results are not directly comparable to earlier work in
the sense that our definitions of IIV varied and we used effect sizes
to rank the utilities of these definitions. For example, while
‘‘inconsistency’’ in performance is often estimated using reaction
time data and then summarized variability across different tests in
terms of the pattern, or dispersion, of test scores (Hilborn et al.,
2009 [6]), in contrast, we summarized variability across different
tests by computing one estimate of IIV, based on each definition,
on combined test performances (see Tables 1A and 1B). In
general, our results are consistent with earlier work in that we have
shown that IIV, derived from within-test item-level performance
or from across test performance, will yield significant effect sizes.
That being said, results of this study are not consistent with those
of Christensen, et al. [2] who found that a mean-independent
estimate of IIV (level-independent variability or LIV) was a useful
summary of performance on a reaction-time based measure This
may be attributable, at least in part, to the very large number of
trials that they used (compared to our study) as well as to the fact
that they were using reaction times, not right/wrong answers to
questions as we have done here.
Neuropsychological test scores may have a great deal of
measurement error (one example is explored in [26]), the
constituent items are not exchangeable, and the typical use to
which these test scores are put - comparing totals over time to
estimate the number of ‘‘points lost,’’ - may have limited
Table 4. Effect size estimates for IIV definitions, and total
scores.
NORMAL vs MCI MCI vs AD
Total score MMSE 1.45 1.95
Total score, Clock 0.530 0.63
ISD MMSE items 1.388 1.660
ISD Clock items 0.630 0.762
ISD 2 totals 0.826 1.182
CV MMSE items 1.426 1.852
CV Clock items 0.939 0.735
CV 2 totals 0.011 0.022
LIV MMSE items 0.232 0.140
LIV Clock items 0 0.426
LIV 2 total scores 0.165 0.077
NOTE: ISD and CV values involving total scores were based on standardized
totals on the two tests (using diagnostic group-specific means and SDs). LIV was
obtained as the square root of the squared standardized residuals from the
regression of the CV on the total score of the test (or, on both total scores, for
the 3
rd LIV value); LIV values were all positive (H. Christensen, personal
communication). IIV estimated based on two total scores were computed using
the standardized version of each score.
doi:10.1371/journal.pone.0016973.t004
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exchangeable and infinitely replicable reaction time trials are
perfectly compatible with measuring intra-individual variability
(IIV), which may provide useful information regarding the
underlying neural integrity of cognitive systems and help predict
incident cognitive decline as well as dementia (e.g. [4,10–17,25]).
Cognitive scientists have suggested that increasing levels of IIV
suggest decreasing levels of brain structure/architectural integrity.
For IIV to be useful in clinical settings, it should differentiate
normal from abnormal cognitive aging (e.g., MCI, AD). Results of
this study suggest that IIV can be estimated from the items within
tests, as well as across cognitive tests, and that the effect size
obtained for IIV will depend on the test and on the definition of
IIV that is used. Importantly, this study also showed that IIV can
be estimated from tests that nearly every NIH-funded Alzheimer’s
(and clinical cognitive aging) study in the United States is already
using, with only the item-level, rather than the total-score level,
information.
Methodological limitations of this study must be noted. First,
only two tests were used to compute estimates of across-test IIV;
this decision was based on the data available and to increase
likelihood of replication in future studies. Additionally, the
majority of studies on IIV conducted to date have employed
reaction-time based tasks. While reaction time tasks may have
greater have sensitivity and reliability in measuring IIV compared
to the MMSE and the Clock Drawing Test, more research is
needed to evaluate this possibility empirically. More research is
also needed to identify the number of tests needed to generate
reliable estimates of across-test IIV (see, e.g., [32]), and
particularly, reliable estimates of clinically meaningful change in
variability. Neuropsychological task specificity (e.g., for different
brain functions or neural circuits, or both) may also need to be
evaluated for the best IIV definition for reliable, longitudinal,
study of cognitive aging (see also [33]).
A second limitation is that clinical grouping was based on
clinical diagnosis. A follow-up study is currently in progress to
replicate findings of the current study in neuropathologically-
confirmed diagnostic groups. Our results suggest that existing
datasets that contain cognitive tests at the item level together with
neuropathology and/or neuroimaging outcomes, can be used to
explore the hypothesis that IIV can represent, for example,
changes in frontal gray matter [13], white matter [14], or
neurotransmission [11,16–17].
A third consideration is the many ways to conceptualize effect
sizes [30–31]; future work will determine the robustness –
particularly with respect to longitudinal, clinically meaningful,
changes in IIV – to the different effect size estimators. Our
analyses have only showed that total scores and the coefficient of
variation –computed at baseline- tend to provide similar predictive
power for 12- and 24-month changes in CDR sum of boxes; we
did not evaluate changes in any of the IIV formulations. It was also
unclear why such a large effect size was observed for total score on
MMSE, although these larger-than-expected effect sizes were also
seen in the MMSE IIV formulations, suggesting the use of MMSE
in intake for these subjects might have skewed the MMSE-related
results.
A fourth consideration is that we chose to simulate data
(generate ‘‘random samples’’) using the mean and SD of the
observed sample as ‘‘population parameters’’ for values following a
normal distribution, rather than conduct a bootstrap which would
have treated our observed means and variances as if they were the
actual population; the bootstrap might have been more support-
able if we had exchangeable and infinitely replicable scores. We
felt that the more clinical-than-cognitive context of our study and
its results supported the simulation approach over the bootstrap
approach. It is possible that a bootstrap would have yielded
different results, but the simulation is consistent with the way data
like ours are used; we will seek to replicate these results in another
sample (using simulation) in future work.
Finally, Schmiedek et al. [34] reported that correcting for either
individual or group means on a reaction time-based estimate of IIV
may lead to incorrect inferences. It is unclear whether the same is
true for IIV estimated as CV (SD/mean) when the task is not
based on reaction times. This is a new, and open, question.
Of interest in Figures 1A and 1B is the unexpectedly large effect
sizes of the MMSE total, i.e., the estimated standardized difference
(Cohen’s d, [30]) was 1.45 for the N vs MCI and 1.95 for the MCI
vs AD comparisons. These are uncharacteristically large effect
sizes, particularly for a general test of cognitive function, in these
cohorts. While wholly beyond the scope of this discussion, this
particular cognitive test is well known to be very noisy and give
very weak effect sizes in general. The IIV-derived ES estimates
were also relatively large in several cases. The very large effect
sizes documented in the figures above could be due to the use of
MMSE in identifying which participants were recruited to the
study from which the data were obtained. It is not used to
diagnose, but is sometimes used as a shorthand way of referring to
–and sometimes recruiting –patients; accordingly, this influence
Table 5. Correlations between observed values of the IIV
formulations and total scores by diagnostic group from their
baseline visits.
NO CLINICAL DIAGNOSIS (N=229)
IIV*: MMSE total CLOCK/COPY total
ITEMS SD 2.935** 2.900**
TOTALS avg SD .556** 2.692**
ITEMS CV 2.953** 2.980**
TOTALS avg CV .042 2.961**
ITEMS LIV 2.337** 2.206**
TOTALS avg LIV 2.057 2.866**
MCI (N=399)
IIV*: MMSE total CLOCK/COPY total
ITEMS SD 2.934** 2.875**
TOTALS avg SD .719** 2.501**
ITEMS CV 2.970** 2.983**
TOTALS avg CV .144** 2.922**
ITEMS LIV .472** 2.316**
TOTALS avg LIV .024 2.485**
AD (N=182)
IIV MMSE total CLOCK/COPY total
ITEMS SD 2.987** 2.740**
TOTALS avg SD .606** 2.600**
ITEMS CV 21.0** 2.974**
TOTALS avg CV .045 2.943**
ITEMS LIV .441** 2.489**
TOTALS avg LIV .094 2.375**
*with respect to appropriate test total.
**p,0.0001.
doi:10.1371/journal.pone.0016973.t005
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PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e16973Figure 1. Mean effect sizes based on 500 replications of simulating 500 ‘‘observations’’ for the nine IIV formulations outlined in the
text. Reference effect size (ES) values are shown giving the value obtained from the observed data for the total test score (flat lines) (Figure 1A: N vs
MCI; Figure 1B: MCI vs AD).
doi:10.1371/journal.pone.0016973.g001
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contrast, the items making up the Clock score were not used to
enroll or diagnose ADNI participants. Its total score-based effect
size were more modest, .54, for normal vs. MCI and .63 for MCI
vs. AD.
A final note is the emphasis in this study on the method of
summary, i.e., total (as proscribed) or some version of variability
(as shown in Tables 1 and 2). The ADNI study is only one of a
large number of similar longitudinal studies presently being
conducted. The level of missingness was very low for ADNI data
at baseline. Because our results were targeting the simulation, and
not so much the original data, we did not address the impact of
missingness on our simulations. However, missingness could only
have affected the results in Table 6 and would likely have driven
our observed-to-be-low estimates further towards zero. These
estimates themselves were not the focus of our work but rather, we
targeted the difference in using the total score vs. a different
summary of the same item level information (i.e., IIV). We did not
address missingness or employ random effects models or any kind
of imputation in the current study. When IIV formulations and
their utility are explored for their use longitudinally, however,
missingness and random effects will be important considerations.
Despite these limitations, results of the current study underscore
the potential utility of item-level and across-test estimates of IIV in
large-scale studies of cognitive aging and dementia. Given that
these data are readily available and being collected in longitudinal
research protocols, estimates of IIV may provide an additional
metric that reflects global neural integrity and may have predictive
utility (e.g., [4,10–17,25]). Definitions of IIV should also be studied
for their performance and characteristics longitudinally; in the
current study, our simulations and analyses were all based on
baseline-data driven IIV estimates. Importantly, although our
regression analyses suggested that the total score and within-test
coefficient of variation (IIV) at baseline did not provide much
explanatory power for change in clinical functioning –and that IIV
generally did not provide explanatory power independent of that
of the total score, effect sizes for IIV as a summary metric were
comparable to ES estimates based on the total scores on these
measures. Our future work will focus on studying the performance
of IIV estimates longitudinally and developing a better under-
standing of how variability in response can represent neural
integrity and neural pathology.
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